The MPP will be attending and taking part in the 7th International AIDS Society conference, to be held in in Kuala Lumpur, Malaysia, between 30 June and 3 July. Sunday 30 June 9:00 – 14:30: Community Forum: ‘Building Partnerships between the Community and Scientists to Strengthen the Response to HIV’. … Read more
12 DECEMBER 2013, GENEVA: The Medicines Patent Pool (MPP) and biopharmaceutical company Bristol-Myers Squibb have signed a licensing agreement to increase access to a key HIV medicine, atazanavir, in 110 developing countries. These countries represent 88.5 percent of people living with HIV/AIDS in developing countries. “This agreement will allow manufacturers … Read more
Sustainable funding for HIV needed to meet needs of people living with HIV but without treatment Continued financing of treatment programmes is essential to get effective, affordable HIV medicines to the 28.6 million people currently needing HIV medicines, two out of three of whom live without the treatment they vitally … Read more
As part of its partnership model, the MPP has been organising a series of events with other stakeholders in the public health field covering key issues. Read Greg Perry’s statement on these events here.
On August 5 2013, The Medicines Patent Pool (MPP) announced an agreement with Swiss pharmaceutical company Roche to increase access to valganciclovir, an important easy-to-take oral medicine to treat cytomegalovirus (CMV). CMV is a viral infection that can cause blindness in people living with HIV. The agreement’s first stage is … Read more